April 7, 2015

Arena Pharmaceuticals shares rise on weight loss drug patent

Shares of Arena Pharmaceuticals rose Tuesday after the drug developer said it received an additional patent for its weight loss drug Belviq.

Arena and its partner Eisai said patent approval was granted from the US Patent and Trademark Office. The patent can prevent other companies from producing a similar drug. The patent is expected to last until 2033, Arena CEO Jack Lief said in a written statement.

Belviq is designed to stimulate serotonin receptors in the brain, making patients feel full. The drug first went on sale in 2013.

San Diego-based Arena Pharmaceuticals Inc. makes and developed Belviq, while Eisai Inc., the U.S. unit of Japanese health company Eisai Co., markets the drug.

Arena shares rose 23 cents, or 5.3 percent, to $4.59 in morning trading Tuesday. Its shares are down 28 percent over the past year.

Citation: Arena Pharmaceuticals shares rise on weight loss drug patent (2015, April 7) retrieved 23 April 2024 from https://medicalxpress.com/news/2015-04-arena-pharmaceuticals-weight-loss-drug.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Weight loss drug Belviq gets overdue US launch

2 shares

Feedback to editors

Study finds suicidal behaviors increased by over 50% in Catalonia, Spain after the COVID-19 pandemic

13 minutes ago

Why do we move slower the older we get? New study delivers answers

43 minutes ago

Stress activates brain regions linked to alcohol use disorder differently for women than men, finds study

48 minutes ago

Chemical tool illuminates pathways used by dopamine, opioids and other neuronal signals

1 hour ago

Gentle defibrillation for the heart: A milder method developed by researchers for cardiac arrhythmias

1 hour ago

Q&A: Research shows neural connection between learning a second language and learning to code

2 hours ago

Gut microbiota acts like an auxiliary liver, study finds

2 hours ago

Higher light levels may improve cognitive performance

2 hours ago

Brain neurons re-entering the cell cycle age quickly and shift to senescence, particularly in neurodegenerative disease

3 hours ago

Study reveals alarming rates of pediatric injuries from mechanical bull riding

3 hours ago

Load comments (0)

Arena Pharmaceuticals shares rise on weight loss drug patent

Study finds suicidal behaviors increased by over 50% in Catalonia, Spain after the COVID-19 pandemic

Why do we move slower the older we get? New study delivers answers

Stress activates brain regions linked to alcohol use disorder differently for women than men, finds study

Chemical tool illuminates pathways used by dopamine, opioids and other neuronal signals

Gentle defibrillation for the heart: A milder method developed by researchers for cardiac arrhythmias

Q&A: Research shows neural connection between learning a second language and learning to code

Gut microbiota acts like an auxiliary liver, study finds

Higher light levels may improve cognitive performance

Brain neurons re-entering the cell cycle age quickly and shift to senescence, particularly in neurodegenerative disease

Study reveals alarming rates of pediatric injuries from mechanical bull riding

Weight loss drug Belviq gets overdue US launch

FDA clears Novo Nordisk's weight loss drug Saxenda

FDA approves weight-loss drug Contrave (Update)

US clears first new weight-loss pill in 13 years

Pfizer painkiller gets longer patent protection (Update)

FDA panel backs Novo Nordisk injection for obesity

Magic mushrooms can treat medication-resistant depression—but are they safe?

Follow-up finds landmark steroid study remains safe 50 years on

Common antibiotic may be helpful in fighting respiratory viral infections

Which treatments for malnutrition's long-term effects could help reduce mortality and health outcomes for children

Ketamine produces wide variety of responses in the brain, researchers find

Antipsychotics for dementia linked to more harms than previously acknowledged

Phys.org

Tech Xplore

Science X

Arena Pharmaceuticals shares rise on weight loss drug patent

Study finds suicidal behaviors increased by over 50% in Catalonia, Spain after the COVID-19 pandemic

Why do we move slower the older we get? New study delivers answers

Stress activates brain regions linked to alcohol use disorder differently for women than men, finds study

Chemical tool illuminates pathways used by dopamine, opioids and other neuronal signals

Gentle defibrillation for the heart: A milder method developed by researchers for cardiac arrhythmias

Q&A: Research shows neural connection between learning a second language and learning to code

Gut microbiota acts like an auxiliary liver, study finds

Higher light levels may improve cognitive performance

Brain neurons re-entering the cell cycle age quickly and shift to senescence, particularly in neurodegenerative disease

Study reveals alarming rates of pediatric injuries from mechanical bull riding

Related Stories

Weight loss drug Belviq gets overdue US launch

FDA clears Novo Nordisk's weight loss drug Saxenda

FDA approves weight-loss drug Contrave (Update)

US clears first new weight-loss pill in 13 years

Pfizer painkiller gets longer patent protection (Update)

FDA panel backs Novo Nordisk injection for obesity

Recommended for you

Magic mushrooms can treat medication-resistant depression—but are they safe?

Follow-up finds landmark steroid study remains safe 50 years on

Common antibiotic may be helpful in fighting respiratory viral infections

Which treatments for malnutrition's long-term effects could help reduce mortality and health outcomes for children

Ketamine produces wide variety of responses in the brain, researchers find

Antipsychotics for dementia linked to more harms than previously acknowledged

Newsletter sign up

Donate and enjoy an ad-free experience